Start 30 days free, no card. Full Pro access for a month, then decide. Start free

Top analysts & firms

All analyzed callsNot limited to the selected quarter · analysts and firms with 2 or more questions

What does “challenging” mean?

Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.

Most active analysts

Analyst	Firm	Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
Vijay Kumar	Evercore ISI	15 questions · 20% challenging
Mike Ryskin	Bank of America	14 questions · 7% challenging
Patrick Donnelly	Citigroup	14 questions · 0% challenging
Dan Leonard	RBC Capital Markets	14 questions · 7% challenging
Puneet Souda	Leerink Partners	13 questions · 8% challenging
Tycho Peterson	Jefferies	12 questions · 8% challenging
Jack Meehan	Operon Research	11 questions · 0% challenging
Dan Brennan	TD Cowen	11 questions · 0% challenging
Brandon Couillard	Wells Fargo	10 questions · 0% challenging
Doug Schenkel	Wolfe Research	9 questions · 22% challenging

Most active firms

Firm	Analysts	Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
Evercore ISI	1 analyst	15 questions · 20% challenging
Jefferies	2 analysts	14 questions · 7% challenging
RBC Capital Markets	1 analyst	14 questions · 7% challenging
Citigroup	1 analyst	14 questions · 0% challenging
Bank of America	1 analyst	14 questions · 7% challenging
Leerink Partners	1 analyst	13 questions · 8% challenging
JPMorgan	2 analysts	11 questions · 0% challenging
Operon Research	1 analyst	11 questions · 0% challenging

Quarter in detail

· FY2026 Q2

Macro Signals

↑Enterprise Spending→Trade & Tariffs↑AI & Tech

Agilent delivered a strong Q2 with $1.83 billion in revenue growing 6.3% core, beating guidance by 80 basis points on broad-based instrument strength including low double digit LC, LCMS, and GC growth. The Ignite operating system drove 130 basis points of operating margin expansion to 26.4% through strategic pricing of approximately 200 basis points and manufacturing overhead reduction exceeding 50 basis points. Management raised full-year EPS guidance by $0.08 to $6.00-$6.10 and core growth guidance by 30 basis points to 4.5-6.0%, reflecting healthy demand in pharma, strong semiconductor-driven CAM growth of 8%, and continued instrument replacement cycle momentum offset by China softness and food market weakness in Asia.

Key Themes7

positive📊 company

Broad-Based Revenue Beat Driven By Instrument Strength

Revenue of $1.83 billion grew 6.3% core, exceeding guidance high end by 80 basis points. Instruments grew high single digits with LC, LCMS, and GC each delivering low double digit growth.

Revenue GrowthDemand

positive📊 company

Ignite Operating System Drives Margin Expansion

Operating margin of 26.4% expanded 130 basis points year over year and 180 basis points sequentially. Strategic pricing delivered approximately 200 basis points in Q2. Manufacturing overhead reduced by more than 50 basis points versus last year.

MarginCost Pressure

positive📊 company

Instrument Replacement Cycle Continues Ninth Quarter

Book-to-bill above 1.0 for the ninth consecutive quarter. LC replacement cycle expected to be a 200-300 bps tailwind to LC growth. GC replacement cycle provides 100 bps tailwind with longer 10-year instrument lifespan.

DemandCompetitive Dynamics

positive🏢 sector

Semiconductor Demand Fuels Advanced Materials Growth

Chemical and advanced materials grew 8% with low double digit growth in advanced materials. Semiconductor is about 30% of the CAM market. Spectroscopy delivered double digit growth from fab and downstream supply chain demand.

DemandCapex Investment

positive📊 company

Innovation Pipeline Accelerating With ASMS Launches

New 9.5 thousand triple quad ICPMS launch pulled forward a full quarter through Ignite. Altura Ultro Inert LC columns grew more than 50% sequentially reaching 75% of top 20 biopharma accounts. OpenLab CDS version 3.0 unifies chromatography, mass spec, and spectroscopy.

Product LaunchInnovation & R&D

negative🌍 macro

China Softness Partially Offsets Broad Growth

China declined 9% in Q2 with larger than expected softness due to Lunar New Year timing. Food declined 3% against mid single digit guide due to delayed government spending in Asia. Food guide lowered from flat to low single digit decline.

DemandMacroeconomic

positive📊 company

Full-Year Guidance Raised On Operational Momentum

Core growth guidance raised to 4.5% to 6.0%, up 30 basis points at midpoint. EPS guidance raised to $6.00 to $6.10, up $0.08 at midpoint representing 7% to 9% growth. Operating margin expansion target raised to 85 basis points.

Revenue GrowthGuidance Reliability

Q&A Topicsfrequency by quarter

	Demand	Revenue Growth	Margin	Macroeconomic	Guidance Reliability	Product Launch	Capex Investment	Geographic Expansion
2024Q4	10	6	2	5	4	4	2	3
2025Q1	8	4	4	4	1	2	1	2
2025Q2	7	3	4	1	2	2	2	2
2025Q3	8	4	5	1	4	2	2	2
2025Q4	11	4	3	2	3	3	4	2
2026Q1	11	6	4	2	4	1	3	1
2026Q2	13	3	2	4	1	2	1

	'24Q4	'25Q1	'25Q2	'25Q3	'25Q4	'26Q1	'26Q2
Demand	10	8	7	8	11	11	13
Revenue Growth	6	4	3	4	4	6	3
Margin	2	4	4	5	3	4	2
Macroeconomic	5	4	1	1	2	2	4
Guidance Reliability	4	1	2	4	3	4	1
Product Launch	4	2	2	2	3	1	2
Capex Investment	2	1	2	2	4	3	1
Geographic Expansion	3	2	2	2	2	1

Analyst Q&A10 analysts · 16 questions

Casey WoodringJPMorgan

would be curious to hear how much that forensic TSA 1-timer you called out was in the quarter. Was that baked into the guide

View in transcript →

Catherine SchulteRobert W. Baird

just given that was the 1 part of the guide that came down. You talked about delays in China and India

View in transcript →

Dan Brennan

View Healthcare sector trends →View Medical - Diagnostics & Research industry trends →

Agilent Technologies A

Sector: Healthcare Industry: Medical - Diagnostics & Research

Low valuation · FY26 Q2

FY26 Q2, sector-relative: P/E 24x (43rd), EV/Sales 18.7x (55th).

CompanyFiscal year ends OctMost recent earnings call: Aug 26, 2026 (FY2026 Q3)Est. next earnings call: Nov 23, 2026

8/ 10

FY2026 Q2Positive+2.0 vs FY2026 Q1

Calendar quarter Q2 2026Earnings call May 27, 2026

FY2026 Q2 in brief

PositiveBroad-Based Revenue Beat Driven By Instrument Strength
PositiveIgnite Operating System Drives Margin Expansion
PositiveInstrument Replacement Cycle Continues Ninth Quarter

Full narrative and all 7 themes ↓

ScoringBase 7 · revenue +10.0%Transcript 0EPS 0Guidance +1Final 8

Newest quarter FY2026 Q3 is part of Pro · see what Pro adds →

Score details · FY2026 Q2

calendar Q2 2026 · call May 27, 2026

Year over year · FY26 Q2 vs FY25 Q2: +2.0 ptsFY26 Q2 8 vs FY25 Q2 6
Analyst challenge ratePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. · all analyzed quarters: 6%

Share price · trailing year

daily closes, last 12 months — not scoped to the selected quarter · dots mark earnings calls, colored by that quarter’s score

A $174.001Y +24.6%YTD +27.9%● earnings calls (score)

Sources. Tellvest earnings-call sentiment score for Agilent Technologies (A), FY2026 Q2: 8/10. Scores: Agilent Technologies’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: A daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.

Key financials

FY2026 Q2 selectedReported GAAP figures from SEC filings

The table scrolls sideways. Swipe it, or select it and use the arrow keys.

Quarter	Revenue	Rev YoY	EPS	EPS YoY	Op margin	Net margin	FCF
FY2024 Q4	$1.70B	+0.8%	$1.22	-24.7%	24.0%	20.6%	$388M
FY2025 Q1	$1.68B	+1.4%	$1.11	-5.9%	22.4%	18.9%	$334M
FY2025 Q2	$1.67B	+6.0%	$0.75	-28.6%	18.0%	12.9%	$107M
FY2025 Q3	$1.74B	+10.1%	$1.18	+21.6%	20.7%	19.3%	$259M
FY2025 Q4	$1.86B	+9.4%	$1.53	+25.4%	23.8%	23.3%	$452M
FY2026 Q1	$1.80B	+7.0%	$1.07	-3.6%	19.6%	17.0%	$175M
FY2026 Q2Selected	$1.83B	+10.0%	$1.20	+60.0%	21.7%	18.5%	$370M
FY2026 Q3	$1.88B	+8.1%	$1.28	+8.5%	23.6%	19.3%	$519M

As stated by management

Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).

EPS: “Earnings per share of $1.49 represents 14% year over year growth”
Revenue: “6.3% on a core or organic constant currency basis”
Guidance: “EPS guidance of $6.00 to $6.10 for the full year, an increase of $0.08 at the midpoint”
Key metric: “Operating margin of 26.4% for the quarter represents a year over year improvement of 130 basis points”

Industry Peersas of Q2 2026

Medical - Diagnostics & Research

Company	Score	Trend	Rev YoY	Headline
A Agilent Technologies	8		+10.0%	Agilent delivered a strong Q2 with $1.83 billion in revenue growing 6.3% core, beating guidance by 80 basis points on broad-based instrument strength including low double digit LC, LCMS, and GC growth
CRL Charles River Laboratories	Newest quarter — available with Pro

Top analysts & firms

Most active analysts

Most active firms

Quarter in detail

Q&A Topicsfrequency by quarter

Companies A discussed

Corporate events

Agilent Technologies A

Score details · FY2026 Q2

Share price · trailing year

Key financials

As stated by management